{"id":756625,"date":"2023-05-09T10:39:39","date_gmt":"2023-05-09T14:39:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/"},"modified":"2023-05-09T10:39:39","modified_gmt":"2023-05-09T14:39:39","slug":"zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/","title":{"rendered":"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of multiple CNS and other inflammatory diseases<\/em>\n        <\/li>\n<li style=\"text-align:left\">\n          <em>Mr. Glover welcomes one-on-one meetings to discuss ZyVersa\u2019s technology, pipeline assets, and key development milestones <\/em>\n        <\/li>\n<\/ul>\n<p align=\"left\">WESTON, Fla., May  09, 2023  (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in the 2023 BIO International Convention being held June 5 &#8211; 8, 2023 in Boston, Massachusetts.<\/p>\n<p align=\"left\">Details for the event are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%;vertical-align: top\">\n            <strong>Event:<\/strong>\n          <\/td>\n<td style=\"max-width:85%;width:85%;min-width:85%;vertical-align: top\">2023 BIO International Convention<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Date:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">Monday, June 5 through Thursday June 8, 2023<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Location:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">Boston Convention and Exhibition Center<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Registration:<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <strong><br \/>\n              <a href=\"https:\/\/www.bio.org\/events\/bio-international-convention\/registration-information\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.bio.org\/events\/bio-international-convention\/registration-information<\/a><br \/>\n            <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\n        <strong>\u00a0<\/strong>\u201cWe are pleased to have the opportunity to meet with our colleagues at the 2023 BIO International Convention as we advance development of our two platform technologies,\u201d stated Mr. Glover. \u201cZyVersa is currently advancing two product candidates, Phase 2a-ready Cholesterol Efflux Mediator\u2122\u00a0VAR 200 designed to ameliorate renal lipid accumulation that damages the kidneys&#8217; filtration system in patients with glomerular diseases, and Inflammasome ASC Inhibitor IC 100 in development to block initiation and perpetuation of damaging inflammation associated with numerous inflammatory diseases.\u201d<\/p>\n<p align=\"left\">To learn more about ZyVersa and its differentiated product pipeline, please schedule a one-on-one meeting with Mr. Glover through the conference portal.<\/p>\n<p align=\"left\">\n        <strong>About ZyVersa Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"left\">ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 developed to ameliorate renal lipid accumulation that damages the kidneys&#8217; filtration system in patients with glomerular kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.<\/p>\n<p align=\"left\">\n        <strong>Cautionary Statement Regarding Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"left\">Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management\u2019s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (\u201cZyVersa\u201d) uses words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cguidance,\u201d and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa\u2019s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa\u2019s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa\u2019s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa\u2019s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa\u2019s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa\u2019s product candidates; ZyVersa\u2019s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa\u2019s ability to protect its intellectual property position; and ZyVersa\u2019s estimates regarding future revenue, expenses, capital requirements and need for additional financing.<\/p>\n<p align=\"left\">New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.<\/p>\n<p align=\"left\">This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.<\/p>\n<p align=\"left\">\n        <strong>Corporate and IR Contact:<\/strong><br \/>\n        <br \/>Karen Cashmere<br \/>Chief Commercial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3LQRwKXFNPuug7R5TuPe9bwJIx4l3TU3yaIcElqTjlHTb4eAHuLaWDYAg1NH27rhaHk2A3PWQJNf_P0OV3aBkl5zZ7vkcTIV6fpu1Y5HBgU=\" rel=\"nofollow noopener\" target=\"_blank\">kcashmere@zyversa.com<\/a><br \/>786-251-9641\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"left\">\n        <strong>Media Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Tiberend Strategic Advisors, Inc.<\/strong><br \/>\n        <br \/>Casey McDonald<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJiKWLbSpLZk1fNF4fGZBY_BVkGxSnjaWqG6xtAXwu1NUSRrjKMiJ4Q70Qg5d9G5AyyCLHTTTf0bBIIMFp5xkEXTpeLZKFbcuk9mCPqeYeA=\" rel=\"nofollow noopener\" target=\"_blank\">cmcdonald@tiberend.com<\/a><br \/>646-577-8520<\/p>\n<p align=\"left\">Dave Schemelia<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5BmlWdsVzcYVVECruKglsyYBvRS3PEceRS8KCqD7pdTP2jK-twQipzJ2ZuszZKGa1MuXrcigFsfb9y_RnrSr6Xd7sJpB7DPWiCJ9fhQlcTU=\" rel=\"nofollow noopener\" target=\"_blank\">dschemelia@tiberend.com<\/a><br \/>609-468-9325<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTA2NWQxNWUtMjM5Mi00YzMwLTgyZGMtMmY5NTM0ZWQxMDI3LTEyNTYwNjk=\/tiny\/ZyVersa-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of multiple CNS and other inflammatory diseases Mr. Glover welcomes one-on-one meetings to discuss ZyVersa\u2019s technology, pipeline assets, and key development milestones WESTON, Fla., May 09, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in the 2023 BIO International Convention being held June 5 &#8211; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-756625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ZyVersa Therapeutics&#039; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZyVersa Therapeutics&#039; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of multiple CNS and other inflammatory diseases Mr. Glover welcomes one-on-one meetings to discuss ZyVersa\u2019s technology, pipeline assets, and key development milestones WESTON, Fla., May 09, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in the 2023 BIO International Convention being held June 5 &#8211; &hellip; Continue reading &quot;ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-09T14:39:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention\",\"datePublished\":\"2023-05-09T14:39:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/\"},\"wordCount\":790,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/\",\"name\":\"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=\",\"datePublished\":\"2023-05-09T14:39:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/","og_locale":"en_US","og_type":"article","og_title":"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention - Market Newsdesk","og_description":"ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of multiple CNS and other inflammatory diseases Mr. Glover welcomes one-on-one meetings to discuss ZyVersa\u2019s technology, pipeline assets, and key development milestones WESTON, Fla., May 09, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in the 2023 BIO International Convention being held June 5 &#8211; &hellip; Continue reading \"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-09T14:39:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention","datePublished":"2023-05-09T14:39:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/"},"wordCount":790,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/","name":"ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=","datePublished":"2023-05-09T14:39:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNDM5MiM1NTgxNzI1IzIyNDQ1MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-ceo-stephen-c-glover-to-participate-in-the-2023-bio-international-convention\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ZyVersa Therapeutics&#8217; CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=756625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=756625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=756625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=756625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}